T cells reinforce NK cell–mediated ADCC
In this issue of Blood, Arora et al report substantial progress in developing an approach to exploit and condition the tumor microenvironment (TME) to enha
In this issue of Blood, Arora et al report substantial progress in developing an approach to exploit and condition the tumor microenvironment (TME) to enha
Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.
Chimeric antigen receptor T-cell (CAR-T) therapy has heralded a transformative era in the treatment of multiple myeloma (MM) following the first relapse. I
Apple cider vinegar, a liquid made from fermenting apples, is said to have many potential health benefits. But what does research say about these claims?…
Axel Hauschild, MD, elucidates the varying role of treatment for both cutaneous cell carcinoma and basal cell carcinoma that are seen globally.
An abstract is unavailable.
Melanoma risks and prevention in people of color: Understand the critical role of awareness, early detection, and the necessity of skin checks.
In this issue of Blood, Touzeau et al report the results of the phase 2 IFM 2018-04 trial of quadruplet induction and double autologous stem cell…
TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.